Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.
Aim(s): Define through a dual high throughput proteomic and transcriptomic approach predictive biomarkers of Everolimus sensitivity.
Materials and methods: Fifteen well-differentiated PNET tumors were minced in 300uM slices and cultured for 48h with no drug, Everolimus or BEZ235. Caspase 3 levels assessed by immunohistochemistry at 48h were used to define sensitive and resistant tumors. Transcriptomic profiles were determined and key oncogenic proteins were quantified by reverse phase protein array (RPPA).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Jerome Cros
, Cros J
, Raffenne J
, Rebours V
, Palazzo M
, Bourgoin P
, Albuquerque M
, Sauvanet A
, Bedossa P
, Ruszniewski P
, Paradis V
, Couvelard A
To read results and conclusion, please login ...
Further abstracts you may be interested in